MARKETSnap
  • Market Snapshots
    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
    • P/E Ratios
      • Large Caps
      • Absolute
      • Total Market PE
    • Stocks Performance
      • Large Caps
      • Absolute
    • Industries Performance
      • Industry
      • Sector
  • Analyze Stock
    • Analyze a stockAnalyze CAPR →
    • FindStock Picks / Stock Screener
    • Value · CAPRIntrinsic Value Calculator
    • Invest · CAPRInvestment Case
    • Hold · CAPR5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding
    Calculator
  • Investing Philosophy
  • More
    • Charts
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
CAPR stock logo

CAPR

Capricor Therapeutics, Inc.

$7.59
0.06
 (0.8%)
Exchange:  NASDAQ
Market Cap:  439.551M
Shares Outstanding:  46.478M
Delayed data
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  BiotechnologyView industry performance
   
CEO:  Linda Marbán
Full Time Employees:  231
Address: 
10865 Road to the Cure
San Diego
CA
92121
US
Website:  https://www.capricor.com
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

It’s free

CAPR full analysis

14/08/2026

Hey everyone, welcome back to MarketSnap. Capricor Therapeutics just went through one of the most violent repricings I've seen in biotech this year, and the dust is nowhere near settled. We're breaking down what the FDA delay really means, why the stock lost three-quarters of its value in a single quarter, and whether the fundamentals still support any kind of bull case. Let's set the stage here, because context matters. Capricor is a clinical-stage biotech out of San Diego, led…

Listen to full analysis (audio file)

Open in MarketSnap Listen

Log in to continue

Log in to see the full analysis preview and audio links.

Log in — it's free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
CACAPR logoCAPRCapricor Therapeutics, Inc.439.6M——-50.8%
CTCTMX logoCTMXCytomX Therapeutics, Inc.442.5M——-29.7%
OCOCS logoOCSOculis Holding AG435.8M——-42.4%
MDMDXG logoMDXGMiMedx Group, Inc.445.1M——-9.7%
DMDMAC logoDMACDiaMedica Therapeutics Inc.445.1M——-143.8%
ANANL logoANLAdlai Nortye Ltd.453.8M——-9.2%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Log in — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/11/10 — 3 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Log in — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue25,178.06622,270.4650
Gross Profit-11,269.973-27,698.1200
EBITDA-21,218.660-39,041.972-100,109.180
Operating Income-24,077.859-42,564.842-108,142.130
Net Income-22,287.542-40,467.186-105,043.946

Log in to continue

Log in to see the income statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets58,734.327170,481.086355,949,294
Total Liabilities36,132.86025,018.75014,320,389
Total Stockholders Equity22,601.467145,462.336305,792,145
Total Debt2,235.8951,451.11414,522,765
Cash and Cash Equivalents14,694.85711,286.996287,847,312

Log in to continue

Log in to see the balance sheet and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-25,596.545-39,995.742-69,811.261
Capital Expenditure-2,047.533-1,538.975-2,904.461
Free Cash Flow-27,644.078-41,534.717-72,715.722
Net Income-22,287.542-40,467.186-105,043.946
Net Change in Cash5,091.615-3,407.861276,560.316

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)26,493.192Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)1,127,458.135Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)478,674.400Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)75,072.088Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)391,146.608Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)201,856.489Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)-19,354.542Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)234,408.783Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)84,869.589Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)197,895.482Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)8,421,743.642Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)3,575,541.263Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)1.830Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)5.040Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)-0.420Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)2Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)1Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access to see up to 5 years of analyst estimates.

Create a free account

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
25.178M  ?P/S
 (TTM)
: 
0
?Net Income
 (TTM)
: 
-22.288M  ?P/E
 (TTM)
: 
-3.61
?Enterprise Value
 (TTM)
: 
599.85M  ?EV/FCF
 (TTM)
: 
-4.1
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
-56.71%  ?ROIC
 (TTM)
: 
-50.85%
?Net Debt
 (TTM)
: 
-80.004M  ?Debt/Equity
 (TTM)
: 
0.44
?P/B
 (TTM)
: 
2.64  ?Current Ratio
 (TTM)
: 
6.77

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Log in — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
N/AResearch AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access for forward P/E high/low estimates and the full multi-year table.

Create a free account

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MarketSnap estimates CAPR intrinsic value between $27.43 – $34.71 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate CAPR Intrinsic Value

Common questions about CAPR valuation

Is Capricor Therapeutics, Inc. (CAPR) overvalued or undervalued right now?

MarketSnap estimates intrinsic value for Capricor Therapeutics, Inc. (CAPR) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is CAPR a buy, hold, or sell for long-term investors?

MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether CAPR trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is CAPR’s P/E ratio?

You can see CAPR’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for CAPR?

MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is CAPR a good long-term investment?

Whether CAPR fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

Research tools for Capricor Therapeutics, Inc.

  • Capricor Therapeutics, Inc. intrinsic value calculatorEstimate what the business is worth
  • Capricor Therapeutics, Inc. 5-year outlookWhat has to go right, and what could go wrong
CAPR

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

0.8
MarketSnap

Trading Metrics:

Open: 8.16   Previous Close: 7.53
Day Low: 7.4   Day High: 8.34
Year Low: 2.96   Year High: 40.37
Price Avg 50: 8.04   Price Avg 200: 19.65
Volume: 10.545M   Average Volume: 6.247M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Log in — it's free
See in Nexus

Relevant news

Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy
20-11-2026 19:55
Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy
Capricor Therapeutics, Inc. (CAPR) Q3 2026 Earnings Call Transcript
10-11-2026 21:41
Capricor Therapeutics, Inc. (CAPR) Q3 2026 Earnings Call Transcript
Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Open-Label Extension Data and Deramiocel Update for Duchenne Muscular Dystrophy Transcript
07-10-2026 20:12
Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Open-Label Extension Data and Deramiocel Update for Duchenne Muscular Dystrophy Transcript
Capricor Highlights Two-Year Deramiocel Data as FDA Decision Nears
07-10-2026 19:02
Capricor Highlights Two-Year Deramiocel Data as FDA Decision Nears
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 28, 2026 in Capricor Therapeutics, Inc. Lawsuit - CAPR
09-09-2026 10:07
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 28, 2026 in Capricor Therapeutics, Inc. Lawsuit - CAPR
CAPR Investor Lawsuit: Capricor Therapeutics Sued for Securities Fraud on behalf of Investors with Losses – Contact BFA Law by September 28 Court Deadline
28-09-2026 05:47
CAPR Investor Lawsuit: Capricor Therapeutics Sued for Securities Fraud on behalf of Investors with Losses – Contact BFA Law by September 28 Court Deadline

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Pricing

How MarketSnap works

What’s new

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
    • Analyze a stockAnalyze CAPR →
    • FindStock Picks / Stock Screener
    • Value · CAPRIntrinsic Value Calculator
    • Invest · CAPRInvestment Case
    • Hold · CAPR5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding Calculator
    • Charts
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Investing Philosophy
  • Nexus
    • Recent Activity
      • Overview
      • My Valuations
      • My Investment Journal
      • Watchlists & Portfolio
    • Plans
    • Settings
    • Public profile ↗
  • Log in
  • Log out

Media

Watch Listen Read
Ask MarketSnap AI

MarketSnap AI Assistant

Uses MarketSnap data and this page

Ready

🔒 You are currently logged out

Login

It's free

MarketSnap Assistant · Tips
    MarketSnap

    Welcome to MarketSnap

    The AI-powered workspace for stock pickers.

    Continue with Google Continue with email

    Already a member? Sign in

    Find stocks·Value them·Build the case·Journal decisions·Track what changes

    Free to join. No card needed. Privacy Policy

    Create your free MarketSnap account Continue with Google
    Chat with us MarketSnap support · account, plans, settings, help
    How MarketSnap works

    The conversation above goes to the MarketSnap team with your message. We reply by e-mail.